Xeris Q2 2026 revenue exceeds $92M
Xeris Biopharma reported $92.1M in Q2 2026 revenue, up 29% year-over-year, driving a revision of full-year guidance to $385M-$390M as Recorlev sales surged.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day